drugset
drugset / Trial / NCT02150070

A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections

NCT02150070 ↗

Phase 1 Completed 32 enrolled Astellas Pharma Global Development, Inc.
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) after intravenous (IV) administration of ASP2408 manufactured from a new production clone and also following single ascending doses of subcutaneous (SC) injections of the same clinical trial material.

Timeline

Start
2011-08
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject ASP2408 Unknown — Intravenous

Indications

No indication recorded.